Exercise in Air Pollution and Lung Health in Asthmatics
Not Applicable
Completed
- Conditions
- Exercise-induced BronchoconstrictionAir Pollution
- Interventions
- Other: Rest (Sitting on chair)Other: Cycling exerciseDrug: Placebo inhalationDrug: Salbutamol inhalationOther: Filtered airOther: Diesel Exhaust Exposure
- Registration Number
- NCT02252302
- Lead Sponsor
- University of British Columbia
- Brief Summary
When exposed to air pollution, the asthma symptoms are aggravated and lung function is impaired. Due to high breathing rates and volumes, physically active individuals are at particular risk of lung health impairment due to the high breathing rates and volumes. Greater doses of air pollutants reach deeper areas in the lungs where they can trigger asthma-symptoms. When treating these symptoms with inhaled beta-2-agonists the airways widen even more, allowing the air pollutants to reach even deeper areas of the lung. With this study the investigators investigate how inhaled beta-2-agonists affect athletic capacity and lung health in physically active asthmatics.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- mild-moderate asthmatics with controlled treatment (definition of "mild": percent fall index at eucapnic voluntary hyperpnea (EVH) test on screening day between 10-15%; "moderate": percent fall index at EVH test on screening day between 15 - 20%).
- men and non-pregnant women
Read More
Exclusion Criteria
- any history of uncontrolled respiratory or cardiac disease
- pregnancy
- allergic reactions to lidocaine and salbutamol
- any recent infections or orthopaedic nasal issues/injuries that may interfere with the insertion of the catheter needed to assess expiratory flow limitation or work of breathing
- claustrophobia in small rooms, comparable to the air pollution chamber used for this study.
- English as a second language (ESL) - participants who are not able to understand the risk that may be associated with the participation in this study due to language difficulties after following the University of British Clinical Research Ethics Board Guidance Notes 13.2.1. (ESL participants will be given a consent form in the most appropriate language or an appropriate translator will be present during the initial consent process).
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Resting in diesel exhaust following salbutamol inhalation Rest (Sitting on chair) Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol. Cycling in diesel exhaust following salbutamol inhalation Diesel Exhaust Exposure Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol. Resting in diesel exhaust following salbutamol inhalation Diesel Exhaust Exposure Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol. Resting in diesel exhaust following placebo inhalation Rest (Sitting on chair) Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo. Resting in diesel exhaust following placebo inhalation Placebo inhalation Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo. Resting in diesel exhaust following placebo inhalation Diesel Exhaust Exposure Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo. Cycling in diesel exhaust following salbutamol inhalation Cycling exercise Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol. Cycling in diesel exhaust following salbutamol inhalation Salbutamol inhalation Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol. Cycling in diesel exhaust following placebo inhalation Cycling exercise Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo Cycling in diesel exhaust following placebo inhalation Placebo inhalation Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo Cycling in diesel exhaust following placebo inhalation Diesel Exhaust Exposure Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo Resting in filtered air following salbutamol inhalation Rest (Sitting on chair) Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol. Resting in filtered air following salbutamol inhalation Filtered air Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol. Resting in filtered air following placebo inhalation Rest (Sitting on chair) Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo. Resting in filtered air following placebo inhalation Filtered air Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo. Cycling in filtered air following salbutamol inhalation Cycling exercise Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol. Cycling in filtered air following salbutamol inhalation Salbutamol inhalation Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol. Cycling in filtered air following salbutamol inhalation Filtered air Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol. Cycling in filtered air following placebo inhalation Cycling exercise Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo Cycling in filtered air following placebo inhalation Placebo inhalation Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo Cycling in filtered air following placebo inhalation Filtered air Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo Resting in diesel exhaust following salbutamol inhalation Salbutamol inhalation Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol.
- Primary Outcome Measures
Name Time Method Change in rating of perceived exertion for breathing, dyspnea Difference in perceived dyspnea between salbutamol and placebo exposure as well as polluted air and filtered air. Dyspnea ratings will be collected every 2.5min for a duration of 45min during the exercise test.
- Secondary Outcome Measures
Name Time Method Change in work of breathing (WOB) between filtered air and polluted air work of breathing will be assessed every 2.5min for a time period of 45min during the exercise bout
Trial Locations
- Locations (1)
University of British Columbia, Environmental Physiology Laboratory
🇨🇦Vancouver, British Columbia, Canada